[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558695":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":26,"locations":32,"responsibleParty":53,"collaborators":23,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":23,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":23,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":23,"overallStatus":34,"whyStopped":23,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Systemic Methotrexate","EXPERIMENTAL","Patients will receive systemic methotrexate (intramuscular; 50 mg\u002Fm2 body weight).",[13],"Drug: Systemic Methotrexate",{"label":15,"type":10,"description":16,"interventionNames":17},"Local Methotrexate","Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).",[18],"Drug: Local Methotrexate",[20,24],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},"DRUG",[9],null,{"type":21,"name":15,"description":16,"armGroupLabels":25,"otherNames":23},[15],[27],{"name":28,"role":29,"phone":30,"phoneExt":23,"email":31},"Mai N Ageez, MD","CONTACT","00201062388870","mai.ageez@med.tanta.edu.eg",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":41,"coordinates":42},"Point",[43,44],31.00192,30.78847,{"lat":44,"lon":43},[47,48,51],{"name":28,"role":29,"phone":30,"phoneExt":23,"email":31},{"name":49,"role":50,"phone":23,"phoneExt":23,"email":23},"Amr A Habib, MD","PRINCIPAL_INVESTIGATOR",{"name":52,"role":50,"phone":23,"phoneExt":23,"email":23},"Shereef L Elshwaikh, MD",{"type":50,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Mai Nabil Ageez","Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Tanta University, Tanta, Egypt.","100558695","local-vs-systemic-methotrexate-in-management-of-uterine-ectopic-pregnancy-100558695",false,"NCT06554470","Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy","Local Versus Systemic Methotrexate in Management of Uterine Ectopic Pregnancy: A Randomized Trial","Inclusion Criteria:\n\n* Age from 20 to 40 years.\n* Women with uterine ectopic pregnancy (interstitial pregnancy, cervical pregnancy, or cesarean scar pregnancy).\n* Gestational age is less than 9 weeks, the embryo size is smaller than 10 mm, and the serum beta-human chorionic gonadotropin (β-hCG) levels are less than 10,000 mIU\u002FmL.\n\nExclusion Criteria:\n\n* Patients with basal beta hCG levels less than 1500 mIU\u002FMl.\n* Any contraindications to MTX as a hepatic disorder, renal disorder and thrombocytopenia\n* Diabetes mellitus.\n* Severe vaginal bleeding or hemodynamic changes or hemoperitoneum.\n* History of cancer.\n* Ascites.\n* Pleural effusion.","FEMALE","20 Years","40 Years",{"count":67,"type":68},34,"ESTIMATED","INTERVENTIONAL",[71],"NA","This study aims to compare local and systemic methotrexate in the management of uterine ectopic pregnancy regarding the duration of beta human chorionic gonadotropin (hCG) clearance and need for further management options.",[74,75,76,77],"Local","Systemic","Methotrexate","Uterine Ectopic Pregnancy","2024-08-15",{"date":80,"type":81},"2024-08-16","ACTUAL",{"date":78,"type":81},{"date":84,"type":68},"2025-07-01",{"name":5,"class":6},1]